AECOM Share Price Target ‘$108.56’, now 21.2% Upside Potential

DirectorsTalk Interviews

AECOM with ticker code (ACM) have now 9 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $116.00 and $100.00 calculating the mean target share price we have $108.56. (at the time of writing). Given that the stocks previous close was at $89.57 and the analysts are correct then we can expect a percentage increase in value of 21.2%. Also worth taking note is the 50 day moving average now sits at $93.99 and the 200 day MA is $88.35. The total market capitalization for the company now stands at 12.27B. The stock price is currently at: $90.14 USD

The potential market cap would be $14,871,991,066 based on the market consensus.

The company has a dividend yield of 0.03%. Other points of data to note are a P/E ratio of 103.61, revenue per share of $111.89 and a 4.65% return on assets.

AECOM is a global provider of professional infrastructure consulting services for governments, businesses, and organizations across the world. The Company operates through three segments: Americas, International, and AECOM Capital (ACAP). The Americas segment provides planning, consulting, architectural and engineering design, and construction and program management services to commercial and government clients in the United States, Canada, and Latin America in end markets, such as transportation, water, government, facilities, environmental, and energy. The International segment offers planning, consulting, architectural and engineering design services and program management to commercial and government clients in Europe, the Middle East, Africa and the Asia-Pacific regions in end markets, such as transportation, water, government, facilities, environmental, and energy. The ACAP segment invests primarily in and develops real estate projects.

Share on:
Find more news, interviews, share price & company profile here for:

    Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

    Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis.

    Dekel Agri-Vision sees record cashew output, higher palm oil prices

    Dekel Agri-Vision has announced a July 2025 update, highlighting record monthly raw cashew nut processing of 533 tonnes at its Tiebissou plant, up 423% from July 2024.

    Diversified Energy delivers strong H1 2025 with Carlyle partnership boost

    Diversified Energy Company posted first-half 2025 results in line with expectations, delivering strong production growth, improved financial metrics, and $152 million in adjusted free cash flow

    EDX Medical Group to complete the development of new pneumonia test

    EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients. 

    Union Jack Oil director increases shareholding

    Union Jack Oil Non-Executive Director Craig Howie has acquired 122,000 shares at 5.075 pence each, raising his total holding to 3,377,000 shares, representing 2.21% of the company’s issued share capital.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

      Search

      Search